Cyclomics is pleased to announce that it has established its advisory board to help the company to shape its strategy for continued growth and development. The advisory board is chaired by Joris Schuurmans, a seasoned executive with long-standing experience in molecular cancer diagnostics, currently serving as Chief Development Officer at SkylineDx, and is furthermore comprised of experienced members with valuable… Read More »Cyclomics appoints advisory board
The research group of Jeroen de Ridder, co-founder of Cyclomics and inventor of CyclomicsSeq technology, has published a research article in Nature. The work describes an elegant use of Oxford Nanopore sequencing to classify paediatric brain tumor by means of real-time analysis of methylation hallmarks. This novel approach enables surgeons to obtain a superfast diagnosis of the tumor, which is… Read More »Cyclomics co-founder Dr. Jeroen de Ridder publishes paper in Nature
In collaboration with KWF, NWO, and Amsterdam UMC, Cyclomics participates in the OralScreen consortium led by Dr. J.B. Poell from the VUMC. OralScreen has the ambition of revolutionizing early cancer detection in the oral cavity. Oral cavity cancers are often detected in a late stage, when the survival chances are severely reduced, affecting the quality of life for the patient.… Read More »The Dutch Cancer Foundation (KWF) granted 1.25M to OralScreen to tackle the diagnostics challenges of oral-cavity cancers.
Research collaboration has resulted in new ‘liquid biopsy’ research workflowusing nanopore sequencing to detect molecules that are associated with cancer,circulating in blood. Thursday 16th March Oxford Nanopore Technologies and Dutch start-up Cyclomics today announced the ‘developeraccess’ of a new research workflow that combines the world’s first nanopore sequencing-basedsolution for ultra-sensitive detection of circulating tumour DNA (ctDNA). The method works by… Read More »Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer
To accelerate the development of innovate technologies in the field of cancer genetic testing, Cyclomics has completed a financing round driven by a group of private investors. In recent years, the primary focus of Cyclomics has been on the development of its core CyclomicsSeq technology, which has found its way in multiple collaborative research projects aimed at detection of genetic… Read More »Cyclomics announces completion of seed financing round